MLchartDataset catalogue

NY-ESO-1-expressing artificial adjuvant vector cells ASP0739

Term · Oncology and biomedicine · MLC-T-ONC-015569

A preparation of artificial adjuvant vector cells (aAVCs) composed of modified human cells engineered to express the tumor-associated antigen (TAA) New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and loaded with loaded with the cluster of differentiation 1d (CD1d) ligand alpha-galactosylceramide (alpha-GalCer; a-GalCer), with potential immunostimulating and antineoplastic activities. Upon administration of the NY-ESO-1-expressing aAVCs ASP0739, the presentation of α-GalCer by CD1d molecules on the cell surface activates invariant NKT (iNKT) cells, thereby eliciting NY-ESO-1-specific NKT cell responses against ASP0739. This in turn activates a natural killer (NK) cell response against NY-ESO-1-expressing tumor cells. In turn, the NY-ESO-1 released from destroyed ASP0739 is taken up by antigen-presenting cells (APCs), mainly by dendritic cells (DCs), which in turn activates NY-ESO-1-specific cytotoxic T lymphocytes (CTL) and results in a CTL-mediated immune response against NY-ESO-1-expressing tumor cells, thereby further destroying NY-ESO-1-expressing tumor cells. In addition, the activation of antigen-specific memory T cells provides long-lasting anti-tumor effects against the NY-ESO-1-expressing tumor cells.

Table 1. Record
IdentifierMLC-T-ONC-015569
FieldOncology and biomedicine
SynonymsaAVC ASP0739; aAVCs ASP0739; NY-ESO-1-expressing aAVCls ASP0739
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015569",
  "term": "NY-ESO-1-expressing artificial adjuvant vector cells ASP0739",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of artificial adjuvant vector cells (aAVCs) composed of modified human cells engineered to express the tumor-associated antigen (TAA) New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and loaded with loaded with the cluster of differentiation 1d (CD1d) ligand alpha-galactosylceramide (alpha-GalCer; a-GalCer), with potential immunostimulating and antineoplastic activities. Upon administration of the NY-ESO-1-expressing aAVCs ASP0739, the presentation of α-GalCer by CD1d molecules on the cell surface activates invariant NKT (iNKT) cells, thereby eliciting NY-ESO-1-specific NKT cell responses against ASP0739. This in turn activates a natural killer (NK) cell response against NY-ESO-1-expressing tumor cells. In turn, the NY-ESO-1 released from destroyed ASP0739 is taken up by antigen-presenting cells (APCs), mainly by dendritic cells (DCs), which in turn activates NY-ESO-1-specific cytotoxic T lymphocytes (CTL) and results in a CTL-mediated immune response against NY-ESO-1-expressing tumor cells, thereby further destroying NY-ESO-1-expressing tumor cells. In addition, the activation of antigen-specific memory T cells provides long-lasting anti-tumor effects against the NY-ESO-1-expressing tumor cells.",
  "synonyms": [
    "aAVC ASP0739",
    "aAVCs ASP0739",
    "NY-ESO-1-expressing aAVCls ASP0739"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ny-eso-1-expressing-artificial-adjuvant-vector-cells-asp0739/"
}

Record 12,045 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.